Related Subjects:
|Drug Toxicity - clinical assessment
|Metabolic acidosis
|Aspirin or Salicylates toxicity
|Ethylene glycol toxicity
|Ethanol toxicity
|Methanol toxicity
|Ricin toxicity
|Carbon Tetrachloride Toxicity
|Renal Tubular Acidosis
|Lactic acidosis
|Iron Toxicity
|Tricyclic Antidepressant Toxicity
|Opiate Toxicity
|Carbon monoxide Toxicity
|Benzodiazepine Toxicity
|Paracetamol (Acetaminophen) toxicity
|Amphetamine toxicity
|Beta Blocker toxicity
|Calcium channel blockers toxicity
|Cannabis toxicity
|Cyanide toxicity
|Digoxin Toxicity
|Lithium Toxicity
|NSAIDS Toxicity
|Ecstasy toxicity
|Paraquat toxicity
|Quinine toxicity
|SSRI Toxicity
|Theophylline Toxicity
|Organophosphate (OP) Toxicity
|Toxin elimination by dialysis
|Drug Toxicity with Specific Antidotes
๐ก Key Point: Hyperkalaemia is a hallmark of severe Digoxin toxicity and correlates with mortality.
Consult the National Poisons Information Service (NPIS) early. Digoxin-specific antibody fragments (Digoxin immune Fab / Digibind) are expensive and may be stocked only in tertiary centres.
๐ About
- Origin: Digoxin is derived from the Digitalis purpurea (foxglove) plant and is also present in oleander and lily of the valley.
- Therapeutic use: Rate control in atrial fibrillation and for symptomatic heart failure in selected patients.
- Therapeutic index: Very narrow โ small changes in dose or renal function can cause toxicity.
โ๏ธ Mechanism & Pathophysiology
- Digoxin inhibits the Naโบ/Kโบ-ATPase pump in cardiac myocytes โ โ intracellular Naโบ โ reduced Naโบ/Caยฒโบ exchange โ โ intracellular Caยฒโบ โ enhanced contractility.
- It also โ vagal tone โ slowed AV nodal conduction and bradycardia.
- Excess inhibition causes electrical instability and automaticity โ arrhythmias of any type.
- Lethal dose: โ10ร daily dose (โ10 mg in adults, โ4 mg in children).
- Tยฝ: 30โ40 h (longer if renal impairment). Toxicity peaks at ~6 h post-ingestion; death may occur within 6โ12 h.
โ ๏ธ Factors Increasing Toxicity
- Electrolytes: โ Kโบ, โ Mgยฒโบ, โ Caยฒโบ enhance binding to Na/K-ATPase.
- Renal impairment: Reduces clearance โ accumulation.
- Drug interactions: Amiodarone, verapamil, macrolides, quinidine increase serum levels.
- Age/frailty: Lower volume of distribution โ toxicity at โtherapeuticโ levels.
๐ฉบ Clinical Presentation
- Gastrointestinal: Anorexia, nausea, vomiting, abdominal pain (early clues).
- Visual: Blurred or yellow vision (xanthopsia), โhaloโ effect.
- Cardiac: Bradycardia, AV block, sinus arrest, SVT with AV block, VT, or VF.
- Neurological: Confusion, weakness, delirium, lethargy.
- Electrolyte: Hyperkalaemia in acute toxicity (poor prognostic sign).
๐งช Investigations
- FBC, U&E, Mg, Ca, renal function.
- Serum digoxin level (โฅ 4 h post ingestion for accuracy).
- ECG: โReverse tickโ ST depression, prolonged PR, frequent ectopics, AV block, or bidirectional VT.
- Continuous cardiac monitoring (CCU/HDU).
๐ซ Management Principles
โ Do NOT give IV calcium unless under senior/NPIS guidance โ may precipitate fatal โstone heartโ contraction.
| Management Step |
Key Actions & Rationale |
| 1๏ธโฃ Stop Digoxin & Decontaminate |
Discontinue digoxin immediately.
If ingestion < 1 h: consider gastric lavage and/or activated charcoal (single or multiple doses for sustained release).
Monitor airway if vomiting or reduced GCS. |
| 2๏ธโฃ Assess & Correct Electrolytes |
Check Kโบ, Mgยฒโบ, Caยฒโบ.
โข Correct hypokalaemia and hypomagnesaemia.
โข Treat hyperkalaemia (Kโบ > 6 mmol/L) with insulin-glucose ยฑ sodium bicarbonate. Avoid calcium unless absolutely indicated. |
| 3๏ธโฃ Cardiac Monitoring & Arrhythmia Control |
- Bradyarrhythmia: IV Atropine 0.6โ1.2 mg; consider temporary pacing if refractory.
- Tachyarrhythmia (VT/VF): Lidocaine or Phenytoin IV.
Avoid Amiodarone or Procainamide (exacerbate toxicity).
- Defibrillation: use low-energy shocks (โ25 J) if needed.
|
| 4๏ธโฃ Antidote โ Digoxin Immune Fab (Digibindยฎ / DigiFabยฎ) |
Indications (per BNF/NPIS):
- Life-threatening arrhythmia or cardiac arrest.
- Serum digoxin > 15 nmol/L (acute ingestion) or > 10 nmol/L (delayed).
- Ingested dose > 10 mg (adult) or > 4 mg (child).
- Hyperkalaemia (Kโบ > 5 mmol/L).
Dose: Each vial binds โ 0.5 mg digoxin; large overdoses may need 10โ20 vials.
Monitor for rebound heart failure once digoxin effect reversed. |
| 5๏ธโฃ Supportive Care |
High-flow Oโ, IV fluids (avoid overload), antiemetics, and correction of precipitating factors (renal impairment, drug interactions). |
| 6๏ธโฃ Monitoring & Follow-up |
Repeat electrolytes and ECG frequently.
Digoxin level becomes unreliable after Fab therapy (immunoassay interference).
Observe โฅ 24 h post-antidote for recurrent bradyarrhythmia or hypokalaemia. |
๐ Prognosis
- With early Fab administration, survival exceeds 90% even in severe overdose.
- Mortality correlates with initial serum potassium and delay to antidote therapy.
- Chronic low-level toxicity (in elderly or renally impaired) often presents subtly with GI upset, confusion, or visual change.
๐ References
Summary: Digoxin toxicity produces a distinctive triad โ gastrointestinal upset, visual changes, and any arrhythmia.
Hyperkalaemia marks severe poisoning.
Management centres on stopping the drug, correcting electrolytes, controlling arrhythmias, and giving Digoxin Immune Fab early in life-threatening cases.